{"success":true,"data":{"pressRelease":{"id":"98849","rtpr_id":"nGNX9w8rX4","ticker":"EMBC","exchange":"NASDAQ","all_tickers":["EMBC"],"title":"$EMBC Lawsuit Notice: BFA Law Reminds Embecta Investors of August 17 Lead Plaintiff Deadline After 57% Stock Drop Triggers Securities Fraud Class Action","author":"Globe Newswire","published_at":"2026-07-27T11:36:00.166Z","article_body":"NEW YORK, July 27, 2026 (GLOBE NEWSWIRE) -- Leading securities law\nfirm Bleichmar Fonti & Auld LLP\n(https://www.globenewswire.com/Tracker?data=KTxdOGPQQWJjvxNsQnvu8W2W3Sv4DkhkrXzk7fau1k5JhIvyIsQlxIEt-FHeOSbvUxaU0iIkpYls49ZGdOfgrYCOoXRMw0GGhXOJ7MvxK5P-NFWsMVL2WDocQ_VijImhxH5BQ7yYaSpCVsDdQCtttPv9LGWWUaJ0gTVPgi1sib8=)\nannounces that a class action lawsuit has been filed against Embecta Corp.\n(NASDAQ:EMBC) and certain of the Company’s senior executives for securities\nfraud after its significant stock drop resulting from potential violations of\nthe federal securities laws.\n\nIf you invested in Embecta, you are encouraged to obtain additional\ninformation by visiting:\nhttps://www.bfalaw.com/cases/embecta-class-action-lawsuit.\n\nKey Details of the Embecta ($EMBC) Class Action:\n* Lead Plaintiff Deadline: August 17, 2026\n* Alleged Misconduct: Securities fraud relating to Embecta’s statements\nabout the strength of its insulin pen needle product category.\n* Largest Alleged Stock Drop: May 5, 2026 – 57.8% Stock Drop\n* Court: U.S. District Court for the District of New Jersey\n* Action: Contact BFA Law\n(https://www.bfalaw.com/cases/embecta-class-action-lawsuit) to discuss your\nrights\nInvestors have until August 17, 2026 to ask the Court to be appointed to lead\nthe case. The complaint asserts securities fraud claims under Sections 10(b)\nand 20(a) of the Securities Exchange Act of 1934 on behalf of investors in\nEmbecta common stock. The class action is pending in the U.S. District Court\nfor the District of New Jersey. It is captioned Apitz-Grossman v. Embecta\nCorp., et al., No. 26-cv-07217.\n\nWhy is Embecta Being Sued for Securities Fraud?\n\nEmbecta is a medical device company that produces insulin pens for patients\nwith diabetes. According to the complaint, during the relevant period, Embecta\ntouted the strength of its insulin pen portfolio stating that “prescriptions\nfor insulin pens have been showing a slight positive trend . . . just\nexemplifying the resilience of this product portfolio.”\n\nAs alleged, in truth, Embecta faced significant competition and “overall\nmarket softness for insulin pens and pen needles.”\n\nWhy did Embecta’s Stock Drop?\n\nOn May 5, 2026, Embecta announced disappointing Q2 2026 results that came in\nbelow guidance due to share loss within its pen needle product category, most\nof which was from a single customer. Embecta also reported an “overall\nmarket volume softness for insulin pens and pen needles in the retail\nchannel,” admitting that “we have now begun to see a decline [for insulin\npens] maybe more pronounced in the most recent quarter that we reported.” As\na result, Embecta also reduced its quarterly dividend from $0.15 to $0.01 per\nshare.\n\nThis news caused the price of Embecta common stock to decline $5.35 per share,\nor 57.8%, from $9.25 per share on May 4, 2026, to $3.90 per share on May 5,\n2026.\n\nClick here for more information:\nhttps://www.bfalaw.com/cases/embecta-class-action-lawsuit.\n\nWhat Can You Do?\n\nIf you invested in Embecta, you may have legal options and are encouraged to\nsubmit your information to the firm.\n\nAll representation is on a contingency fee basis; there is no cost to you.\nShareholders are not responsible for any court costs or expenses of\nlitigation. The firm will seek court approval for any potential fees and\nexpenses.\n\nSubmit your information by visiting:\n\nhttps://www.bfalaw.com/cases/embecta-class-action-lawsuit\n\nOr contact:\nAdam McCall\nadam@bfalaw.com\n212.789.3619\n\nWhy Bleichmar Fonti & Auld LLP?\n\nBFA is a leading international law firm representing plaintiffs in securities\nclass actions and shareholder litigation. It has been named a top plaintiff\nlaw firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have\nbeen named “Elite Trial Lawyers” by the National Law Journal,\n“Litigation Stars” by Benchmark Litigation, among the top “500 Leading\nPlaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’\nBar” by Law360 and “SuperLawyers” by Thomson Reuters.\n\nMost recently, The Legal 500 awarded BFA the most client satisfaction\naccolades of any plaintiff’s securities litigation law firm, with clients\nnoting: “[t]here is no better service provider in the practice area,”\n“[t]he interest of the client is always front and center,” and “[t]here\nisn’t a better firm in this space.” One testimonial described the firm as\n“nimble and entrepreneurial,” with a “relentless focus on adding value\nfor clients.”\n\nAmong its recent notable successes, BFA recovered over $900 million in value\nfrom Tesla, Inc.’s Board of Directors, as well as $420 million from Teva\nPharmaceutical Ind. Ltd.\n\nFor more information about BFA and its attorneys, please visit\nhttps://www.bfalaw.com.\n\nhttps://www.bfalaw.com/cases/embecta-class-action-lawsuit\n\nAttorney advertising. Past results do not guarantee future outcomes.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/44a256cf-d470-4d8a-af6b-dbb1b5bbb11e)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX9w8rX4","title":"$EMBC Lawsuit Notice: BFA Law Reminds Embecta Investors of August 17 Lead Plaintiff Deadline After 57% Stock Drop Triggers Securities Fraud Class Action","author":"Globe Newswire","ticker":"EMBC","created":"2026-07-27T11:36:00.166Z","tickers":["EMBC"],"exchange":"NASDAQ","article_body":"NEW YORK, July 27, 2026 (GLOBE NEWSWIRE) -- Leading securities law\nfirm Bleichmar Fonti & Auld LLP\n(https://www.globenewswire.com/Tracker?data=KTxdOGPQQWJjvxNsQnvu8W2W3Sv4DkhkrXzk7fau1k5JhIvyIsQlxIEt-FHeOSbvUxaU0iIkpYls49ZGdOfgrYCOoXRMw0GGhXOJ7MvxK5P-NFWsMVL2WDocQ_VijImhxH5BQ7yYaSpCVsDdQCtttPv9LGWWUaJ0gTVPgi1sib8=)\nannounces that a class action lawsuit has been filed against Embecta Corp.\n(NASDAQ:EMBC) and certain of the Company’s senior executives for securities\nfraud after its significant stock drop resulting from potential violations of\nthe federal securities laws.\n\nIf you invested in Embecta, you are encouraged to obtain additional\ninformation by visiting:\nhttps://www.bfalaw.com/cases/embecta-class-action-lawsuit.\n\nKey Details of the Embecta ($EMBC) Class Action:\n* Lead Plaintiff Deadline: August 17, 2026\n* Alleged Misconduct: Securities fraud relating to Embecta’s statements\nabout the strength of its insulin pen needle product category.\n* Largest Alleged Stock Drop: May 5, 2026 – 57.8% Stock Drop\n* Court: U.S. District Court for the District of New Jersey\n* Action: Contact BFA Law\n(https://www.bfalaw.com/cases/embecta-class-action-lawsuit) to discuss your\nrights\nInvestors have until August 17, 2026 to ask the Court to be appointed to lead\nthe case. The complaint asserts securities fraud claims under Sections 10(b)\nand 20(a) of the Securities Exchange Act of 1934 on behalf of investors in\nEmbecta common stock. The class action is pending in the U.S. District Court\nfor the District of New Jersey. It is captioned Apitz-Grossman v. Embecta\nCorp., et al., No. 26-cv-07217.\n\nWhy is Embecta Being Sued for Securities Fraud?\n\nEmbecta is a medical device company that produces insulin pens for patients\nwith diabetes. According to the complaint, during the relevant period, Embecta\ntouted the strength of its insulin pen portfolio stating that “prescriptions\nfor insulin pens have been showing a slight positive trend . . . just\nexemplifying the resilience of this product portfolio.”\n\nAs alleged, in truth, Embecta faced significant competition and “overall\nmarket softness for insulin pens and pen needles.”\n\nWhy did Embecta’s Stock Drop?\n\nOn May 5, 2026, Embecta announced disappointing Q2 2026 results that came in\nbelow guidance due to share loss within its pen needle product category, most\nof which was from a single customer. Embecta also reported an “overall\nmarket volume softness for insulin pens and pen needles in the retail\nchannel,” admitting that “we have now begun to see a decline [for insulin\npens] maybe more pronounced in the most recent quarter that we reported.” As\na result, Embecta also reduced its quarterly dividend from $0.15 to $0.01 per\nshare.\n\nThis news caused the price of Embecta common stock to decline $5.35 per share,\nor 57.8%, from $9.25 per share on May 4, 2026, to $3.90 per share on May 5,\n2026.\n\nClick here for more information:\nhttps://www.bfalaw.com/cases/embecta-class-action-lawsuit.\n\nWhat Can You Do?\n\nIf you invested in Embecta, you may have legal options and are encouraged to\nsubmit your information to the firm.\n\nAll representation is on a contingency fee basis; there is no cost to you.\nShareholders are not responsible for any court costs or expenses of\nlitigation. The firm will seek court approval for any potential fees and\nexpenses.\n\nSubmit your information by visiting:\n\nhttps://www.bfalaw.com/cases/embecta-class-action-lawsuit\n\nOr contact:\nAdam McCall\nadam@bfalaw.com\n212.789.3619\n\nWhy Bleichmar Fonti & Auld LLP?\n\nBFA is a leading international law firm representing plaintiffs in securities\nclass actions and shareholder litigation. It has been named a top plaintiff\nlaw firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have\nbeen named “Elite Trial Lawyers” by the National Law Journal,\n“Litigation Stars” by Benchmark Litigation, among the top “500 Leading\nPlaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’\nBar” by Law360 and “SuperLawyers” by Thomson Reuters.\n\nMost recently, The Legal 500 awarded BFA the most client satisfaction\naccolades of any plaintiff’s securities litigation law firm, with clients\nnoting: “[t]here is no better service provider in the practice area,”\n“[t]he interest of the client is always front and center,” and “[t]here\nisn’t a better firm in this space.” One testimonial described the firm as\n“nimble and entrepreneurial,” with a “relentless focus on adding value\nfor clients.”\n\nAmong its recent notable successes, BFA recovered over $900 million in value\nfrom Tesla, Inc.’s Board of Directors, as well as $420 million from Teva\nPharmaceutical Ind. Ltd.\n\nFor more information about BFA and its attorneys, please visit\nhttps://www.bfalaw.com.\n\nhttps://www.bfalaw.com/cases/embecta-class-action-lawsuit\n\nAttorney advertising. Past results do not guarantee future outcomes.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/44a256cf-d470-4d8a-af6b-dbb1b5bbb11e)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-07-27T11:36:00.213215729Z","server_sent_at_ms":1785152160213},"received_at":"2026-07-27T11:36:00.308Z","source_url":null},"analysis":{"id":"87889","press_release_id":"98849","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":["Plaintiff law-firm solicitation","Alleged 57.8% stock drop","Dividend cut from $0.15 to $0.01"],"eventType":"legal_litigation","narrative":"Bleichmar Fonti & Auld LLP announced a class action lawsuit against Embecta Corp. regarding alleged securities fraud tied to statements about its insulin pen needle portfolio strength.\n\nThe lawsuit follows a reported 57.8% stock drop on May 5, 2026, which occurred after the company reported disappointing Q2 results and cut its quarterly dividend from $0.15 to $0.01.\n\nInvestors have until August 17, 2026, to seek lead plaintiff status in the U.S. District Court for the District of New Jersey.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{"customDimensions":{"case_number":"26-cv-07217","dividend_prior":"$0.15","dividend_reduced":"$0.01","post_stock_price":"$3.90","prior_stock_price":"$9.25","stock_drop_percent":"57.8%","stock_decline_amount":"$5.35","lead_plaintiff_deadline":"August 17, 2026"}},"quotedText":"","namedEntities":{"people":[{"name":"Adam McCall","role":"Attorney"}],"products":["insulin pens","pen needles"],"companies":[{"name":"Embecta Corp.","ticker":"EMBC","relationship":"defendant"},{"name":"Bleichmar Fonti & Auld LLP","relationship":"plaintiff law firm"},{"name":"Tesla, Inc.","ticker":"TSLA","relationship":"mentioned in law firm bio"},{"name":"Teva Pharmaceutical Ind. Ltd.","ticker":"TEVA","relationship":"mentioned in law firm bio"}],"dollarAmounts":[{"amount":"$0.15","context":"prior quarterly dividend per share"},{"amount":"$0.01","context":"reduced quarterly dividend per share"},{"amount":"$5.35","context":"decline in stock price per share"},{"amount":"$9.25","context":"stock price on May 4, 2026"},{"amount":"$3.90","context":"stock price on May 5, 2026"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm solicitation. The release is a boilerplate reminder for investors to join a class action lawsuit; no new material disclosure originates from the issuer."},"tickerRelevance":{"others":[],"primary":"EMBC"},"globalImportance":15,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Bleichmar Fonti & Auld LLP announced a class action lawsuit against Embecta Corp. regarding alleged securities fraud tied to statements about its insulin pen needle portfolio strength.\n\nThe lawsuit follows a reported 57.8% stock drop on May 5, 2026, which occurred after the company reported disappointing Q2 results and cut its quarterly dividend from $0.15 to $0.01.\n\nInvestors have until August 17, 2026, to seek lead plaintiff status in the U.S. District Court for the District of New Jersey.","key_figures":{"customDimensions":{"case_number":"26-cv-07217","dividend_prior":"$0.15","dividend_reduced":"$0.01","post_stock_price":"$3.90","prior_stock_price":"$9.25","stock_drop_percent":"57.8%","stock_decline_amount":"$5.35","lead_plaintiff_deadline":"August 17, 2026"}},"named_entities":{"people":[{"name":"Adam McCall","role":"Attorney"}],"products":["insulin pens","pen needles"],"companies":[{"name":"Embecta Corp.","ticker":"EMBC","relationship":"defendant"},{"name":"Bleichmar Fonti & Auld LLP","relationship":"plaintiff law firm"},{"name":"Tesla, Inc.","ticker":"TSLA","relationship":"mentioned in law firm bio"},{"name":"Teva Pharmaceutical Ind. Ltd.","ticker":"TEVA","relationship":"mentioned in law firm bio"}],"dollarAmounts":[{"amount":"$0.15","context":"prior quarterly dividend per share"},{"amount":"$0.01","context":"reduced quarterly dividend per share"},{"amount":"$5.35","context":"decline in stock price per share"},{"amount":"$9.25","context":"stock price on May 4, 2026"},{"amount":"$3.90","context":"stock price on May 5, 2026"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-07-27T12:16:59.654Z","global_importance":15,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":345162,"modelName":"glm-4.7"}}